Abstract:Accurate prediction of oral pharmacokinetics remains challenging. This study investigated quantitative approaches for the prediction of the area under the plasma concentration–time curve after oral administration (AUCp,oral) to rats using the in vitro–in vivo extrapolation (IVIVE), in silico model using machine learning approaches and the combination of the in silico model and in vitro data. A set of 595 structurally diverse compounds with determined AUCp,oral at 1 mg/kg, in vitro intrinsic clearance (CLint), an unbound fraction in plasma (fu,p) in rats, and kinetic solubility at pH 6.8 was used for this assessment. Prediction models developed by two different types of machine learning techniques (i.e., random forest regression and Gaussian processes) were evaluated using three validation methods implementing the time and cluster-split training and test set and fivefold cross-validation. The developed machine learning models have a square of correlation coefficient (R2) in the range of 0.381–0.685 with 33–45% of the compounds being predicted within 2-fold of the observed AUCp,oral value. The predictivity was improved by incorporating CLint, fu,p, and solubility as explanatory variables with R2 = 0.554–0.743. In cases where extraction by the liver is the main elimination pathway and intestinal extraction is negligible, AUCp,oral can be expressed by dose, CLint, and fu,p based on a well-stirred model. By using this conventional IVIVE approach, only 1.7–5.0% of compounds were predicted within the 2-fold error with R2 = 0.354–0.487. Two empirical scaling factors (ESFs) determined by linear regression analysis and machine learning approaches improved the predictivity of AUCp,oral with 33–44% predicted within twofold variability. The IVIVE using ESF predicted by random forest regression showed better predictivity of AUCp,oral with R2 = 0.471–0.618, while it still showed lower predictivity than machine learning approaches applied directly to AUCp,oral prediction. This study demonstrated that the combination of in silico and in vitro parameters is useful to improve the predictivity of the machine learning model for rat AUCp,oral and supports consideration for predicting AUCp,oral for human and other non-clinical species in a similar manner.This article has not yet been cited by other publications.

Prediction of Oral Pharmacokinetics Using a Combination of In Silico Descriptors and In Vitro ADME Properties

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

In Silico Prediction of Human Intravenous Pharmacokinetic Parameters with Improved Accuracy

A Novel Chemometric Method for the Prediction of Human Oral Bioavailability

Prediction of Hepatic Plasma Clearance in Vivo from Gel-Entrapped Rat and Human Hepatocytes.

Computational Predictions of Nonclinical Pharmacokinetics at the Drug Design Stage

Prediction of Compound Plasma Concentration–Time Profiles in Mice Using Random Forest

Recent developments of in silico predictions of oral bioavailability.

Computational modeling of human oral bioavailability: what will be next?

Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds

ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules?

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution

Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios

Evaluation of models for predicting drug-drug interactions due to induction

Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery

Prediction of drug bioavailability in humans using immobilized artificial membrane phosphatidylcholine column chromatography and in vitro hepatic metabolic clearance

Prediction Model of Clearance by a Novel Quantitative Structure–Activity Relationship Approach, Combination DeepSnap-Deep Learning and Conventional Machine Learning

ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints.

Prediction of Human Clearance Using In Silico Models with Reduced Bias

Artificial intelligence for compound pharmacokinetics prediction

A deep neural network: mechanistic hybrid model to predict pharmacokinetics in rat